Flu Vaccine Effectiveness and COVID-19 Vaccine Sales Decline

Two new analyses provide evidence supporting the use of high-dose flu vaccines for older adults. The first study, published in *The Lancet*, revealed that vaccinating 515 older adults with HD-IIV instead of SD-IIV could prevent one all-cause hospitalization. The second study, published in the *International Journal of Infectious Diseases*, found that Italian older adults receiving HD-IIV reported fewer lab-confirmed influenza cases compared to those vaccinated with SD-IIV.

Meanwhile, Pfizer reported a 25% decrease in U.S. sales of its Comirnaty COVID-19 vaccine. This decline is attributed to revised recommendations from the CDC, which now leave the decision to get vaccinated up to individual patients. Experts suggest that anti-vaccine sentiment and confusion about the necessity of boosters contribute to the reduced demand. The change in government guidance has also raised questions about insurance coverage, though major industry groups have clarified that the shots will continue to be covered.

Pharmacy owners note increased confusion among customers, with many expressing uncertainty about who to believe regarding vaccine information. This confusion, coupled with declining infection rates for COVID-19, has led to a significant drop in sales for both Pfizer's vaccine and its COVID-19 treatment, Paxlovid.

Yes, studies show high-dose flu vaccines provide better protection against hospitalization and infection in older adults compared to standard-dose vaccines.

Factors include narrowed recommendations from health authorities, anti-vaccine sentiment, confusion about booster necessity, and declining infection rates.

Do you think high-dose flu vaccines should be the standard for older adults? How has the changing guidance affected your decision to get vaccinated against COVID-19? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!